Insights Into Diffuse Large B-Cell Lymphoma (DLBCL)

Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape

Southwest – February 22, 2021
Purchase Report

Faculty Chair

John Burke, MD

Rocky Mountain Cancer Centers, Colorado Springs, CO

Central – April 21, 2021
Purchase Report

Faculty Chair

Manali Kamdar, MD

University of Colorado Hospital, Aurora, CO

Midwest – October 7, 2021
Purchase Report

Faculty Chair

Matthew Lunning, DO, FACP

University of Nebraska Medical Center, Omaha, NE

More Information

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

  • Virtual Series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual Series
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Indiana, Ohio

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of diffuse large b-cell lymphoma (DLBCL)
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, polatuzumab vedotin

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.